^
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Glioma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
GBM
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
IDH1 mutation + ATRX deletion + TP53 deletion
Glioma
CAN-3110
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
No biomarker
GBM
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Brain Cancer
lomustine
Sensitive: A1 - Approval
No biomarker
Astrocytoma
everolimus
Sensitive: A1 - Approval
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive: A1 - Approval
No biomarker
GBM
bevacizumab
Sensitive: A1 - Approval
No biomarker
GBM
temozolomide
Sensitive: A1 - Approval
No biomarker
GBM
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
GBM
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
GBM
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Glioma
teserpaturev
Sensitive: A1 - Approval
VHL mutation
CNS Tumor
belzutifan
Sensitive: A1 - Approval
No biomarker
GBM
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
BRAF V600E
GBM
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
GBM
PCV
Sensitive: A2 - Guideline
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive: A2 - Guideline
No biomarker
Glioma
PCV
Sensitive: A2 - Guideline
MGMT promoter methylation
GBM
temozolomide
Sensitive: A2 - Guideline
No biomarker
Oligodendroglioma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Glioma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Meningioma
bevacizumab + everolimus
Sensitive: A2 - Guideline
No biomarker
Meningioma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Meningioma
sunitinib
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + vincristine + lomustine
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Glioma
bevacizumab
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Astrocytoma
lomustine + procarbazine hydrochloride + vincristine liposomal
Sensitive: A2 - Guideline
No biomarker
GBM
lomustine
Sensitive: A2 - Guideline
No biomarker
GBM
regorafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
No biomarker
Astrocytoma
temozolomide gel
Sensitive: A2 - Guideline
BRAF V600E
Glioma
selumetinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
dabrafenib
Sensitive: A2 - Guideline
NTRK3 fusion
Glioma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Glioma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Glioma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Glioma
lomustine
Sensitive: A2 - Guideline
NTRK3 fusion
Glioma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Glioma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Glioma
entrectinib
Sensitive: A2 - Guideline
BRAF V600E
GBM
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF fusion
Glioma
selumetinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
No biomarker
Ependymoma
lomustine
Sensitive: A2 - Guideline
No biomarker
Ependymoma
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Glioma
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cyclophosphamide
Sensitive: A2 - Guideline
No biomarker
Ependymoma
lapatinib
Sensitive: A2 - Guideline
No biomarker
Ependymoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Ependymoma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Meningioma
DG3173
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
vismodegib
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cisplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
etoposide oral
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Medulloblastoma
carboplatin + cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
No biomarker
GBM
VAL-083
Sensitive: B - Late Trials
No biomarker
GBM
enzastaurin
Sensitive: B - Late Trials
No biomarker
GBM
DNX-2401
Sensitive: B - Late Trials
H3.3K27M
Glioma
ONC201
Sensitive: B - Late Trials
No biomarker
GBM
GDC-0084
Sensitive: B - Late Trials
MGMT unmethylation
GBM
temozolomide
Sensitive: B - Late Trials
IDH1 mutation
Glioma
temozolomide gel
Sensitive: B - Late Trials
IDH1 R132H
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
IDH2 mutation
Glioma
temozolomide
Sensitive: B - Late Trials
IDH1 mutation
Glioma
temozolomide
Sensitive: B - Late Trials
MGMT promoter methylation
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
IDH2 mutation
Glioma
temozolomide gel
Sensitive: B - Late Trials
IDH1 mutation
Glioma
PCV
Sensitive: B - Late Trials
IDH2 mutation
Glioma
PCV
Sensitive: B - Late Trials
No biomarker
GBM
GLR2007
Sensitive: B - Late Trials
No biomarker
GBM
VB-111
Sensitive: B - Late Trials
No biomarker
Glioma
OKN-007
Sensitive: B - Late Trials
No biomarker
GBM
CYNK-001
Sensitive: B - Late Trials
No biomarker
GBM
VBI-1901
Sensitive: B - Late Trials
No biomarker
GBM
RTA 744
Sensitive: B - Late Trials
No biomarker
Medulloblastoma
CX-4945
Sensitive: B - Late Trials